Santander agrees to acquire TSB from Sabadell for £2.65 billion

Ana Botín Group Executive Chair Santander Group
Ana Botín Group Executive Chair - Santander Group
0Comments

Santander has announced an agreement to acquire TSB Banking Group plc from Banco de Sabadell, S.A. for £2.65 billion in an all-cash transaction. This acquisition will enhance Santander’s presence in the UK market by expanding its customer base and lending capacity.

TSB is a well-established UK retail bank with 218 branches and a growing digital presence, serving around 5 million customers. The acquisition will make Santander UK the third largest bank in personal current account balances and fourth in mortgages.

Ana Botín, Banco Santander’s executive chair, commented on the transaction: “Banco Santander’s executive chair.”

The deal is expected to create significant value for shareholders through increased scale, access to low-risk mortgages, high-quality deposits, and operational efficiencies. It aims to generate a return on invested capital of over 20% and increase return on tangible equity from 11% in 2024 to 16% by 2028.

Cost synergies are projected at £400 million pre-tax, with restructuring costs of £520 million during 2026 and 2027. The transaction is expected to be accretive to earnings per share from the first year.

Mike Regnier, CEO of Santander UK, said: “Mike Regnier, CEO of Santander UK.”

Santander has experience integrating banking platforms successfully in the past and expects this acquisition to unlock operational efficiencies through technology integration.

The transaction requires regulatory approvals and Sabadell shareholder approval and is expected to complete in early 2026.



Related

Paul Hudson Chief Executive Officer Sanofi SA

Acoziborole receives key EU panel backing as single-dose treatment for sleeping sickness

Acoziborole Winthrop, a new oral treatment for sleeping sickness developed by the Drugs for Neglected Diseases initiative (DNDi) and Sanofi, has received a positive opinion from the European Medicines Agency’s Committee for Medicinal Products for…

Martin Lundstedt President and CEO at Volvo Group North America LLC Volvo Group North America LLC

Volvo announces updated share and vote count after series conversion

The number of votes in AB Volvo has changed following the conversion of 2,000,619 Series A shares into an equal number of Series B shares.

Paul Hudson Chief Executive Officer Sanofi SA

Sanofi and Regeneron’s Dupixent recommended for EU approval in young children with chronic urticaria

Sanofi and Regeneron have announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending approval of Dupixent (dupilumab) for children aged two to 11 years with…

Trending

The Weekly Newsletter

Sign-up for the Weekly Newsletter from EU Business Daily.